Victims of the infamous blood-thinner Xarelto keep mounting up. A new Xarelto lawsuit has been filed by a man in Georgia, Louisiana against Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson), the pharmaceutical companies that manufactured the dangerous Novel Oral Anticoagulant (NOAC). The plaintiff accuses the Big Pharma of the death of his father, who allegedly died because of an uncontrollable bleeding event consequent to the use of Xarelto.
Federal Xarelto bleeding lawsuits kept accruing, reaching over 2,000 total cases in the last few years. All the Xarelto litigations have been consolidated in the Multi-District Litigation (MDL nNumber 2592) in the United States District Court for the Eastern District of Louisiana, in New Orleans, presided over by Judge Eldon Fallon. Additional class action mass tort claims have been formed in Philadelphia, Pennsylvania to speed up the legal proceedings that include several similar allegations against the drug manufacturers. Four cases chosen as the most representative ones will be heard during bellwether trials. The first two trials will be held on February 6, 2017, and March 13, 2017, in the Eastern District of Louisiana; the third on has been scheduled on April 24, 2017, in Mississippi; and the fourth on May 30, 2017, in Texas.
Xarelto is in fact often associated with several cases of internal bleedings and haemorrhages, whose consequence included serious injuries to the patients and, in some instances, even their death. Xarelto has been approved by the Food and Drugs Administration (FDA) for the prevention of blood clots and stroke during atrial fibrillation, and for the treatment and prevention of pulmonary embolism and deep venous thrombosis. However, the absence of a proper antidote makes Xarelto a dangerous medication in the event of an internal bleeding. Once its effects cause and haemorrhage, in fact, there’s no way to revert them as a constant transfusion of fresh platelets or Vitamin K are ineffective.
The complaint number 2:15-cv-00886, was filed on March 20th of 2015, in the state of Louisiana. The patient died after an uncontrollable internal bleeding event, just a few time after being prescribed Xarelto to treat his atrial fibrillation. The patient’s son explained that they had no idea that Xarelto was so dangerous, and that nobody explained them the potential consequences of using this medication. Not knowing this information prevented he and his family to make a properly informed choice about using or not this type or treatment. The lack of a proper safety warning could be considered as negligence from Bayer and Janssen Pharmaceutica.